PriceTargets.com logo

OKYO Pharma - OKYO Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: GBX 0
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
GBX 1.40 As of 05/19/2023 08:39 PM ET
▼ -0.45 (-24.32%)

This chart shows the closing price for OKYO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New OKYO Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for OKYO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for OKYO

Analyst Price Target is GBX 0
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for OKYO Pharma in the last 3 months. The average price target is GBX 0, with a high forecast of GBX 0 and a low forecast of £100,000. The average price target represents a -100.00% upside from the last price of GBX 1.40.

This chart shows the closing price for OKYO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in OKYO Pharma. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/29/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/27/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/25/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/23/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/21/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/29/2019Shore CapitalReiterated RatingHouse Stock
(Data available from 11/21/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
4/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
OKYO Pharma logo
OKYO Pharma Limited, a preclinical biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead product includes OK-101 for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.
Read More

Today's Range

Now: GBX 1.40
Low: 1.40
High: 1.98

50 Day Range

MA: GBX 1.40
Low: 1.40
High: 1.40

52 Week Range

Now: GBX 1.40
Low: 1.35
High: 8.50

Volume

364,142 shs

Average Volume

431,999 shs

Market Capitalization

£23.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of OKYO Pharma?

The following Wall Street sell-side analysts have issued reports on OKYO Pharma in the last twelve months:
View the latest analyst ratings for OKYO.

What is the current price target for OKYO Pharma?

0 Wall Street analysts have set twelve-month price targets for OKYO Pharma in the last year. has the lowest price target set, forecasting a price of £100,000 for OKYO Pharma in the next year.
View the latest price targets for OKYO.

What is the current consensus analyst rating for OKYO Pharma?

OKYO Pharma currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for OKYO.

What other companies compete with OKYO Pharma?

Other companies that are similar to OKYO Pharma include Pharos Energy, Open Orphan, Alpha Real Trust, Kodal Minerals and Aggregated Micro Power. Learn More about companies similar to OKYO Pharma.

How do I contact OKYO Pharma's investor relations team?

OKYO Pharma's physical mailing address is 55 PARK LANE, LONDON, X0, W1K 1NA. The company's listed phone number is 44 20 7495 2379. The official website for OKYO Pharma is www.okyopharma.com. Learn More about contacing OKYO Pharma investor relations.